1. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981. doi: 10.1111/j.1468-1331.2009.02748.x
2. Samsam M. Drugs against calcitonin gene-related peptide and its receptor used in the treatment of migraine: What are the new progresses? Neuro Open J. 2015; 2: 79-91. doi: 10.17140/NOJ-2-117
3. Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015; 14(10): 1010-1022. doi: 10.1016/S1474-4422(15)00198-2
4. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995; 1: 658-660. doi: 10.1038/nm0795-658
5. Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Expert Rev Neurother. 2006; 6: 1159-1171. doi: 10.1586/14737175.6.8.1159
6. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007; 13: 39-44. doi: 10.1016/j.molmed.2006.11.005
7. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-584. doi: 10.1038/nrn3057
8. Samsam M. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem. 2012; 12: 158-172. doi: 10.2174/187152412802430147
9. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994; 117 (Pt 1): 199-210. doi: 10.1093/brain/117.1.199
10. Tfelt-Hansen PC. History of migraine with aura and cortical spreading depression from 1941 and onwards. Cephalalgia. 2010; 30(7): 780-92. doi: 10.1111/j.1468-2982.2009.02015.x
11. Lauritzen M, Strong AJ. ‘Spreading depression of Leão’ and its emerging relevance to acute brain injury in humans. J Cereb Blood Flow Metab. 2016; pii: 0271678X16657092. doi: 10.1177/0271678X16657092
12. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996; 87: 543-552. doi: 10.1016/S0092-8674(00)81373-2
13. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33: 192-196. doi: 10.1038/ng1081
14. Vanmolkot KR, Kors EE, Hottenga JJ, et al. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol. 2003; 54: 360-366. doi: 10.1002/ana.10674
15. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005; 366: 371-377. doi: 10.1016/S0140-6736(05)66786-4
16. Kors EE, Vanmolkot KR, Haan J, et al. Recent findings in headache genetics. Curr Opin Neurol. 2004; 17: 283-288. Web site. http://journals.lww.com/co-neurology/Abstract/2004/06000/Recent_findings_in_headache_genetics.8.aspx. Accessed December 27, 2016.
17. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004; 41: 701-710. doi: 10.1016/S0896-6273(04)00085-6
18. Olsen J. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 241: 9-160.
19. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015; 14(1): 65-80. doi: 10.1016/S1474-4422(14)70220-0
20. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9): 629-808.
21. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995; 15(5): 384-390. doi: 10.1046/j.1468-2982.1995.1505384.x
22. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11): 1104-1110. doi: 10.1056/NEJMoa030505
23. Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004; 24: 645-656. doi: 10.1111/j.1468-2982.2004.00726.x
24. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123. doi: 10.1016/S0140-6736(08)61626-8
25. Ho TW, Mannix LK, Fan X, et al. MK-0974 Protocol 004 study group. Collaborators (20), Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312. doi: 10.1212/01.WNL.0000286940.29755.61
26. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977. doi: 10.1212/WNL.0b013e3181b87942
27. Salvatore CA, Moore EL, Calamari A, et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010; 333: 152-160. doi: 10.1124/jpet.109.163816
28. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722. doi: 10.1177/0333102411398399
29. Diener HC, Barbanti P, Dahlöf C, et al. BI44370TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia. 2011; 31: 573-84. doi: 10.1177/0333102410388435
30. Leahy DK, Fan Y, Desai LV, et al. Efficient and scalable enantioselective synthesis of a CGRP antagonist. Org Lett. 2012; 14: 4938-4941. doi: 10.1021/ol302262q
31. Luo G, Chen L, Conway CM, et al. Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine. ACS Med Chem Lett. 2012; 3: 337-341. doi: 10.1021/ml300021s
32. Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016; 36: 887-898. doi: 10.1177/0333102416653233
33. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13: 885-892. doi: 10.1016/S1474-4422(14)70128-0
34. Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomized, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-1
35. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.Cephalalgia. 2013; 34(7): 483-492. doi: 10.1177/033310241351777
36. Bigal ME, Dodick DW, Krymchantowski AV, et al. TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016; 87(1): 41-88. doi: 10.1212/WNL.0000000000002801
37. BigalME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6): 886-895. doi: 10.1111/bcp.12591
38. Ferrari MD, Färkkilä M, Reuter U, et al. European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan–a randomized proof-of-concept trial. Cephalalgia. 2010; 30: 1170-1178. doi: 10.1177/0333102410375512
39. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010; 30: 1159-1169. doi: 10.1177/0333102410370873
40. Färkkilä M, Diener HC, Géraud G, et al. COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012; 11(5): 405-413. doi: 10.1016/S1474-4422(12)70047-9
41. Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs. 2014; 28: 11-17. doi: 10.1007/s40263-013-0126-2
42. Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep. 2015; 15(5): 25. doi: 10.1007/s11910-015-0547-z
43. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016; 5: 637. doi: 10.1186/s40064-016-2211-8
44. Starling AJ, Vargas BB. A narrative review of evidence-based preventive options for chronic migraine. Curr Pain Headache Rep. 2015; 19(10):49. doi: 10.1007/s11916-015-0521-0
45. Picaza JA, Cannon BW, Hunter SE, Boyd AS, Guma J, Maurer D. Pain suppression by peripheral nerve stimulation. Part I. Observations with transcutaneous stimuli. Surg Neurol. 1975; 4(1): 105-114. doi: 10.1159/000102446
46. Picaza JA, Cannon BW, Hunter SE, Boyd AS, Guma J, Maurer D. Pain suppression by peripheral nerve stimulation. Part II. Observations with implanted devices. Surg Neurol. 1975; 4(1): 115-126.
47. Picaza JA, Hunter SE, Cannon BW. Pain suppression by peripheral nerve stimulation. Chronic effects of implanted devices. Appl Neurophysiol. 1977-1978; 40(2-4): 223-234. doi: 10.1159/000102446
48. Lou L. Uncommon areas of electrical stimulation for pain relief. Curr Rev Pain. 2000; 4(5): 407-412. doi: 10.1007/s11916-000-0025-3
49. Van Calenbergh F, Gybels J, Van Laere K, et al. Long term clinical outcome of peripheral nerve stimulation in patients with chronic peripheral neuropathic pain. Surg Neurol. 2009; 72(4): 330-335. doi: 10.1016/j.surneu.2009.03.006
50. Stanton-Hicks M, Salamon J. Stimulation of the central and peripheral nervous system for the control of pain. J Clin Neurophysiol. 1997; 14(1): 46-62. doi: 10.1097/00004691-199701000-00004
51. Stojanovic MP. Stimulation methods for neuropathic pain control. Curr Pain Headache Rep. 2001; 5(2): 130-137. doi: 10.1007/s11916-001-0081-3
52. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: A synthesis of the central structures involved in migraine. Headache. 1991; 31(6): 365-371. doi: 10.1111/j.1526-4610.1991.hed3106365.x
53. Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation. 1999; 2(3): 217-221. doi: 10.1046/j.1525-1403.1999.00217.x
54. Nörenberg E, Winkelmüller W. The epifacial electric stimulation of the occipital nerve in cases of therapy-resistant neuralgia of the occipital nerve. Schmerz. 2001; 15(3): 197-199. doi: 10.1007/s004820170023
55. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011; 31(3): 271-285. doi: 10.1177/0333102410381142
56. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012; 32(16): 1165-1179. doi: 10.1177/0333102412462642
57. Miller S, Watkins L, Matharu M. Long-term outcomes of occipital nerve stimulation for chronic migraine: A cohort of 53 patients. J Headache Pain. 2016; 17(1): 68. doi: 10.1186/s10194-016-0659-0
58. Clark SW, Venkatesan L, Boorman D, et al. 189 Comparison of efficacy of tonic and burst occipital nerve stimulation in treating trigeminal allodynia: Chronic Result. Neurosurgery. 2016; 63(Suppl 1): 175. doi: 10.1227/01.neu.0000489758.97532.6a
59. Slotty PJ, Bara G, Kowatz L, et al. Occipital nerve stimulation for chronic migraine: A randomized trial on subthreshold stimulation. Cephalalgia. 2015; 35(1): 73-78. doi: 10.1177/0333102414534082
60. Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: What is the rationale? Cephalalgia. 2014; 34(5): 382-391. doi: 10.1177/0333102413512032
61. Piagkou M, Demesticha T, Troupis T, et al. The pterygopalatine ganglion and its role in various pain syndromes: From anatomy to clinical practice. Pain Pract. 2012; 12(5): 399-412. doi: 10.1111/j.1533-2500.2011.00507.x
62. Klein RN, Burk DT, Chase PF. Anatomically and physiologically based guidelines for use of the sphenopalatine ganglion block versus the stellate ganglion block to reduce atypical facial pain. Cranio. 2001; 19(1): 48-55. doi: 10.1080/08869634.2001.11746151
63. Schoenen J. Sphenopalatine ganglion stimulation in neurovascular headaches. Prog Neurol Surg. 2015; 29: 106-116. doi: 10.1159/000434661
64. Goadsby PJ. Sphenopalatine ganglion stimulation increases regional cerebral blood flow independent of glucose utilization in the cat. Brain Res. 1990; 506(1): 145-148. doi: 10.1016/0006-8993(90)91211-X
65. Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarinia M. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache. 2009; 49(7): 983-989. doi: 10.1111/j.1526-4610.2009.01451.x
66. Fox EJ, Melzack R. Transcutaneous electrical stimulation and acupuncture: Comparison of treatment for low-back pain. Pain. 1976; 2(2): 141-148. doi: 10.1016/0304-3959(76)90109-3
67. Magora F, Aladjemoff L, Tannenbaum J, Magora A. Treatment of pain by transcutaneous electrical stimulation. Acta Anaesthesiol Scand. 1978; 22(6): 589-592. doi: 10.1111/j.1399-6576.1978.tb01341.x
68. Cook IA, Abrams M, Leuchter AF. Trigeminal nerve stimulation for comorbid posttraumatic stress disorder and major depressive disorder. Neuromodulation. 2016; 19(3): 299-305. doi: 10.1111/ner.12399
69. Schoenen J, Roberta B, Magis D, Coppola G. Noninvasive neurostimulation methods for migraine therapy: The available evidence. Cephalalgia. 2016; pii: 0333102416636022. doi: 10.1177/0333102416636022
70. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology. 2013; 80(8): 697-704. doi: 10.1212/WNL.0b013e3182825055
71. Riederer F, Penning S, Schoenen J. Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly® device for migraine prevention: A Review of the available data. Pain Ther. 2015; 4(2): 135-147. doi: 10.1007/s40122-015-0039-5
72. Russo A, Tessitore A, Conte F, et al. Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: The first Italian experience. J Headache Pain. 2015; 16: 69. doi: 10.1186/s10194-015-0551-3
73. Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: A survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013; 14: 95. doi: 10.1186/1129-2377-14-95
74. Magis D, D’Ostilio K, Thibaut A, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 2016. pii: 0333102416656118. doi: 10.1177/0333102416656118
75. Vonck K, Van Laere K, Dedeurwaerdere S, et al. The mechanism of action of vagus nerve stimulation for refractory epilepsy: The current status. J Clin Neurophysiol. 2001; 18(5): 394-401. doi: 10.1097/00004691-200109000-00002
76. Vonck K, Boon P, Van Roost D. Anatomical and physiological basis and mechanism of action of neurostimulation for epilepsy. Acta Neurochir Suppl. 2007; 97(Pt 2): 321-328. doi: 10.1007/978-3-211-33081-4_35
77. Bohning DE, Lomarev MP, Denslow S, Nahas Z, Shastri A, George MS. Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI. Invest Radiol. 2001; 36(8): 470-479. doi: 10.1097/00004424-200108000-00006
78. Ko D, Heck C, Grafton S, et al. Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H2(15)O blood flow imaging. Neurosurgery. 1996; 39(2): 426-430. doi: 10.1097/00006123-199608000-00061
79. Henry TR, Bakay RA, Votaw JR, et al. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia. 1998; 39(9): 983-990. doi: 10.1111/j.1528-1157.1998.tb01448.x
80. Narayanan JT, Watts R, Haddad N, Labar DR, Li PM, Filippi CG. Cerebral activation during vagus nerve stimulation: A functional MR study. Epilepsia. 2002; 43(12): 1509-1514. doi: 10.1046/j.1528-1157.2002.16102.x
81. Hord ED, Evans MS, Mueed S, Adamolekun B, Naritoku DK. The effect of vagus nerve stimulation on migraines. J Pain. 2003; 4(9): 530-534. doi: 10.1016/j.jpain.2003.08.001
82. Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia. 2005; 25(2): 82-86. doi: 10.1111/j.1468-2982.2005.00611.x
83. Cecchini AP, Mea E, Tullo V, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: Preliminary data. Neurol Sci. 2009; 30(1): S101-S104. doi: 10.1007/s10072-009-0073-3
84. Mosqueira AJ, López-Manzanares L, Canneti B, et al. Vagus nerve stimulation in patients with migraine. Rev Neurol. 2013; 57(2): 57-63.
85. Ness TJ, Fillingim RB, Randich A, Backensto EM, Faught E. Low intensity vagal nerve stimulation lowers human thermal pain thresholds. Pain. 2000; 86(1-2): 81-85. doi: 10.1016/s0304-3959(00)00237-2
86. Chen SP, Ay I, de Morais AL, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016; 157(4): 797-805. doi: 10.1097/j.pain.0000000000000437
87. Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. Cephalalgia. 2014; 34(12): 986-993. doi: 10.1177/0333102414524494
88. Barbanti P, Grazzi L, Egeo G, et al. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: An open-label study. J Headache Pain. 2015; 16: 61. doi: 10.1186/s10194-015-0542-4
89. Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): A randomized, monocentric clinical trial. J Headache Pain. 2015; 16: 543. doi: 10.1186/s10194-015-0543-3
90. Kinfe TM, Pintea B, Muhammad S, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: A prospective observational cohort study. J Headache Pain. 2015; 16: 101. doi: 10.1186/s10194-015-0582-9
91. Silberstein SD, Calhoun AH, Lipton RB, et al. EVENT Study Group. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016; 87(5): 529-538. doi: 10.1212/WNL.0000000000002918
92. Gaul C, Diener HC, Silver N, et al. PREVA Study Group. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia. 2016; 36(6): 534-546. doi: 10.1177/0333102415607070
93. Knyihár-Csillik E, Tajti J, Samsam M, Sáry G, Slezák S, Vécsei L. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res. 1997; 48(5): 449-464.
94. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain. 2000; 84(2-3): 389-395. doi: 10.1016/s0304-3959(99)00240-7
95. Samsam M, Coveñas R, Csillik B, et al. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; A possible neurophysiological and neuroanatomical link to generalized head pain. J Chem Neuroanat. 2001; 21(2): 161-169. doi: 10.1016/S0891-0618(01)00088-6
96. Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016; 113(29): 8284-8289. doi: 10.1073/pnas.1605635113
97. Rösler KM, Hess CW, Schmid UD. Investigation of facial motor pathways by electrical and magneticstimulation: Sites and mechanisms of excitation. J Neurol Neurosurg Psychiatry. 1989; 52(10): 1149-1156. doi: 10.1136/jnnp.52.10.1149
98. Mills KR, Murray NM, Hess CW. Magnetic and electrical transcranial brain stimulation: Physiological mechanisms and clinical applications. Neurosurgery. 1987; 20(1): 164-168. doi: 10.1097/00006123-198701000-00033
99. Lo YL. Headache: Migraine, magnetic stimulation and cortical excitability. Nat Rev Neurol. 2010; 6(8): 425-427. doi: 10.1038/nrneurol.2010.109
100. Bhola R, Kinsella E, Giffin N, et al. Single-pulsetranscranial magnetic stimulation (sTMS) for the acute treatment of migraine: Evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015; 16: 535. doi: 10.1186/s10194-015-0535-3
101. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulsetranscranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010; 9(4): 373-380. doi: 10.1016/S1474-4422(10)70054-5
102. Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain. 2016; 139(Pt 7): 2002-2014. doi: 10.1093/brain/aww118
103. Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: A safety review. Headache. 2010; 50(7): 1153-1163. doi: 10.1111/j.1526-4610.2010.01697.x
104. Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013; 53(8): 1300-1311. doi: 10.1111/head.12154
105. Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan use on developing chronic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013; 53(10): 1548-1563. doi: 10.1111/head.12201
106. Berger A, Bloudek LM, Varon SF, Oster G. Adherence with migraine prophylaxis in clinical practice. Pain Pract. 2012; 12(7): 541-549. doi: 10.1111/j.1533-2500.2012.00530.x
107. Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol. 2016; 12(11): 635-650. doi: 10.1038/nrneurol.2016.143
108. Magis D, Bruno MA, Fumal A, et al. Central modulation in cluster headache patients treated with occipital nerve stimulation: An FDG-PET study. BMC Neurol. 2011; 11: 25. doi: 10.1186/1471-2377-11-25
109. Samsam M, Coveñas R, Ahangari R, Yajeya J. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. AIAA-MC. 2010; 3: 170-188. doi: 10.2174/1871523011009030170
110. Contreras RJ, Beckstead RM, Norgren R. The central projections of the trigeminal, facial, glossopharyngeal and vagus nerves: An autoradiographic study in the rat. J Auton Nerv Syst. 1982; 6(3): 303-322. doi: 10.1016/0165-1838(82)90003-0
111. Lyubashina OA, Sokolov AY, Panteleev SS. Vagal afferent modulation of spinal trigeminal neuronal responses to dural electrical stimulation in rats. Neuroscience. 2012; 222: 29-37. doi: 10.1016/j.neuroscience.2012.07.011
112. Bossut DF, Maixner W. Effects of cardiac vagal afferent electrostimulation on the responses of trigeminal and trigeminothalamic neurons to noxious orofacial stimulation. Pain. 1996; 65(1): 101-109. doi: 10.1016/0304-3959(95)00166-2
113. Puledda F, Goadsby PJ. Current approaches to neuromodulation in primary headaches: Focus on vagal nerve and sphenopalatine ganglion stimulation. Curr Pain Headache Rep. 2016; 20(7): 47. doi: 10.1007/s11916-016-0577-5
114. Martelletti P, Jensen RH, Antal A, et al. European Headache Federation. Neuromodulation of chronic headaches: Position statement from the European Headache Federation. J Headache Pain. 2013; 14: 86. doi: 10.1186/1129-2377-14-86